ClinicalTrials.gg
Active, not recruitingNCT05462717Updated May 15, 2026

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

A Phase 1 interventional study of RMC-6291 in Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines, Inc.. Active, not recruiting at 64 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Revolution Medicines, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
222
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. — 8 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Revolution Medicines, Inc..

Planned enrollment
9th of 13
222 · median 430
Started
2022
with 1 other
Phase 1
5 of 13
2 open now
Registered
6th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., this one is the 9th largest by planned enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

Read the detailed description

This is an open-label, multicenter, Phase 1/1b study of RMC-6291 monotherapy in subjects with advanced KRASG12C-mutant solid tumors. The study will include 2 components: a Dose-Escalation and a Dose-Expansion. Subjects will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumor

Keywords

  • RMC-6291
  • RAS(ON)
  • KRAS
  • KRASG12C
  • KRASG12C(ON)
  • Targeted therapy
  • Metastatic cancer
  • Lung Cancer
  • Lung Neoplasms
  • Thoracic Neoplasms
  • Non-small Cell Lung Cancer
  • Carcinoma, Non-Small Cell Lung
  • NSCLC
  • Colorectal Cancer
  • Colonic Neoplasms
  • CRC
  • Appendiceal Cancer
  • KRAS mutation
  • STK11/LKB1
  • KEAP1
  • bronchial neoplasms
  • respiratory tract neoplasms
  • neoplasms by site
  • neoplasms
  • Colon Cancer
  • Rectal Cancer
  • lung disease
  • respiratory tract diseases
  • Pancreatic Cancer
  • Carcinoma, Pancreatic Ductal
  • PDAC
  • Gastrointestinal Neoplasms
  • Intestinal Neoplasms
  • Esophageal cancer
  • Ampullary cancer
  • Gastric Cancer
  • Gynecological Cancer
  • Ovarian Cancer
  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be ≥18 years of age.
  • Subject must have documented, locally advanced or KRASG12C-mutated solid tumor (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
  • performance status 0 or 1
  • Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation and for NSCLC in dose expansion
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system (CNS) tumors
  • Active
  • Known impairment of GI function that would alter the absorption
  • Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
  • Prior therapy with KRASG12C (ON) inhibitor

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    RMC-6291

    Dose Escalation and Dose Expansion

    Drug: RMC-6291

Interventions

  • Oral tablet once or twice a day

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of participants with adverse events

    Time frame: up to 3 years

  2. Dose Limiting Toxicities

    Number of participants with dose limiting toxicities

    Time frame: The first 21 days (i.e. Cycle 1)

Secondary outcomes

  1. Maximum Observed Blood Concentration of RMC-6291

    Cmax

    Time frame: 7 Cycles

  2. Time to Reach Maximum Blood Concentration of RMC-6291

    Tmax

    Time frame: 7 Cycles

  3. Area Under Blood Concentration Time Curve of RMC-6291

    AUC

    Time frame: 7 Cycles

  4. Elimination Half-Life of RMC-6291

    t1/2

    Time frame: 7 Cycles

  5. Ratio of accumulation of RMC-6291 from a single dose to steady state with repeated dosing

    accumulation ratio

    Time frame: 7 Cycles

  6. Overall Response Rate (ORR)

    Overall response rate per RECIST v1.1

    Time frame: 3 years

  7. Duration of Response (DOR)

    Duration of response per RECIST v1.1

    Time frame: 3 years

  8. Disease Control Rate (DCR)

    Disease control rate per RECIST v1.1

    Time frame: 3 years

  9. Time to Response (TTR)

    Time to response per RECIST v1.1

    Time frame: 3 years

  10. Progression-Free Survival (PFS)

    Progression-free survival per RECIST v1.1

    Time frame: 3 years

07

Study locations

64 sites
08

References and documents

Publications

  • Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, Tomlinson A, Choy TJ, Wang Z, Sang B, Pourfarjam Y, Lucas J, Cuevas-Navarro A, Ayala-Santos C, Vides A, Li C, Marquez A, Zhong M, Vemulapalli V, Weller C, Gould A, Whalen DM, Salvador A, Milin A, Saldajeno-Concar M, Dinglasan N, Chen A, Evans J, Knox JE, Koltun ES, Singh M, Nichols R, Wildes D, Gill AL, Smith JAM, Lito P. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023 Aug 18;381(6659):794-799. doi: 10.1126/science.adg9652. Epub 2023 Aug 17. PubMed 37590355 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 54 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 54 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 18, 2022
StartActual
Sep 19, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05462717
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Sep 19, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 15, 2026

Study contacts

Revolution Medicines, Inc.
study director · Revolution Medicines, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elironrasib

Start the discussion